Autolus Therapeutics PLC - American Depositary Shares (AUTL) closed at $1.32 on November 9, 2026, up 3.1% from the previous close, on volume of 4,261,567 shares (30-day average 1,895,442).
Data as of November 9, 2026.
9-Nov-2026
Here are the major earnings before the open Tuesday
Seeking Alpha News (Mon, 9-Nov 6:00 PM ET)
Autolus Therapeutics Q3 2026 Earnings Preview
Seeking Alpha News (Mon, 9-Nov 9:32 AM ET)
Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference
Globe Newswire (Mon, 9-Nov 7:15 AM ET)
Alphabet maintains massive SpaceX bet, initiates $548M Qualcomm stake
Seeking Alpha News (Mon, 9-Nov 12:47 AM ET)
Globe Newswire (Wed, 4-Nov 9:15 AM ET)
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Tue, 3-Nov 4:45 PM ET)
Globe Newswire (Mon, 26-Oct 4:15 PM ET)
Globe Newswire (Mon, 5-Oct 8:30 AM ET)
Globe Newswire (Wed, 9-Sep 7:00 AM ET)
AUTL Raises FY26 Guidance as AUCATZYL Revenue Surges 119%—Gross Margins Hit 55% in Q2
Market Chameleon (Tue, 11-Aug 7:19 AM ET)
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
Autolus Therapeutics PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol AUTL.
As of November 9, 2026, AUTL stock price climbed to $1.32 with 4,261,567 million shares trading.
AUTL has a beta of 3.60, meaning it tends to be more sensitive to market movements. AUTL has a correlation of 0.36 to the broad based SPY ETF.
AUTL has a market cap of $351.02 million. This is considered a Small Cap stock.
Last quarter Autolus Therapeutics PLC - American Depositary Shares reported $46 million in Revenue and -$.15 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.04.
In the last 3 years, AUTL traded as high as $7.45 and as low as $1.11.
The top ETF exchange traded funds that AUTL belongs to (by Net Assets): IBB, CANC, GWX, QQQS, APIE.
AUTL has underperformed the market in the last year with a price return of -2.9% while the SPY ETF gained +13.4%. AUTL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -34.0% and -14.3%, respectively, while the SPY returned -1.8% and -1.0%, respectively.
AUTL support price is $1.22 and resistance is $1.34 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AUTL shares will trade within this expected range on the day.
